The FrontlineODP™ development program is funded by the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services under contract HHS0100201200005C . Velico is grateful for its partnership with BARDA without whom the development of this life saving technology would not be possible.
Velico is developing a breakthrough, platform technology for manufacturing spray dried human plasma. The FrontlineODP™ system is intended to be deployed at regional blood centers who will produce dry plasma (versus freezing it, the current standard) for use by hospitals, emergency first responders and the military. Dry plasma will be a logistically superior product which extends the availability of plasma from the hospital to the point of injury, including rural and austere settings.
FDP will be easily reconstituted with 200 to 250 ml of sterile water (SW), will not be affected by forceful shaking during reconstitution, and will be able to be used within minutes, making it practical in the prehospital and early hospital settings where fresh plasma is unavailable.
Plasma transfusions are lifesaving in critical care and the treatment of many types of trauma which result in blood loss and uncontrolled haemorrhage. Uncontrolled bleeding is recognized as the leading cause of potentially preventable death among victims of trauma. The early administration of plasma has been demonstrated to be lifesaving for many of these patients.
Sed sem libero, sodales in lamcorper bibendum, feugiat id lorem usce orci purus, consequat id arcu vitae, iaculis sagittis odales in lamcorper bibendum.
If you are a blood center, hospital, investor or interested in learning more about Velico, please click the button below to submit a request.